AbbVie Submits Biologics License Application To The FDA For Telisotuzumab Vedotin In Previously Treated Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
AbbVie has submitted a Biologics License Application to the FDA for Teliso-V, an investigational drug for previously treated non-small cell lung cancer with c-Met protein overexpression. If approved, it would be the first therapy for this specific cancer type.
September 27, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie has submitted a BLA for Teliso-V, targeting a specific type of NSCLC. If approved, it would be the first therapy for c-Met overexpressing NSCLC, potentially boosting AbbVie's oncology portfolio.
The submission of a BLA for Teliso-V represents a significant step for AbbVie in addressing a specific unmet need in NSCLC treatment. If approved, it would be the first therapy for c-Met overexpressing NSCLC, potentially enhancing AbbVie's position in the oncology market. The FDA's RTOR program could expedite the review process, increasing the likelihood of a positive short-term impact on AbbVie's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100